While the high rate of systemic effects (mainly gastrointestinal) due to systemic cholinergic stimulation may limit compliance to AChE inhibitors, the risk of long-term effects, including QT prolongation, is unknown in CHF patients [97]. The gene discussed is ACHE; the disease is congestive heart failure.